professionalIMG

Daniel T. Kajunski

Member vCard


Education

  • Suffolk University (JD, 1998)
  • Saint Anselm College (BA, 1994)

Bar Admissions

  • Massachusetts

Dan’s practice focuses primarily on venture finance, securities law and offerings, mergers and acquisitions, and general business and corporate law, primarily for life sciences and technology companies.

VCs, strategic investors, and issuers rely on Dan’s extensive experience in private fund raising, including equity and debt financings. Public companies also turn to him in connection with public and private offerings and their securities law and compliance needs. In addition, both buyers and sellers engage Dan to counsel them in complicated mergers and acquisitions. Dan also regularly advises both private and public companies at various stages of development on general corporate matters.

Prior to joining the firm, Dan served as a law clerk to the justices of the Superior Court of Massachusetts. While in law school, he served as a staff author and comment editor for the Suffolk University Law Review.

Representative Matters

Offerings for Public Companies

  • Represented Vertex Pharmaceuticals (Nasdaq: VRTX) in over $2.0 billion in equity and debt offerings since 2006
  • Represented ImmunoGen (Nasdaq: IMGN) in approximately $350 million in equity offerings since 2008
  • Represented Amedica (Nasdaq: AMDA) in its IPO
  • Represented the underwriters in the IPO of Calithera Biosciences (Nasdaq: CALA)
  • Represented the underwriters in the IPO of American Depositary Shares of GW Pharmaceuticals (Nasdaq: GWPH) and two additional follow-on offerings

Venture Capital & Strategic Financings

  • Represented a public technology company in the semiconductor and life sciences industry (Nasdaq) in multiple strategic investments
  • Represented a public medical device company (NYSE) in multiple strategic investments
  • Represented Clarus Ventures in its investments in Ophthotech (Nasdaq: OPHT), VBI Vaccines (Nasdaq: VBIV), TyRx Pharma, and Link Medicine
  • Represented a public biotechnology company (Nasdaq) in its strategic equity investment in a private biotechnology company
  • Represented Style Me Pretty in its strategic investment from AOL (NYSE: AOL)
  • Represented Synchroneuron in multiple equity financings
  • Represented TransMolecular in multiple equity and debt financings
  • Represented Ion Torrent Systems in multiple equity financings
  • Represented I-Pulse in multiple equity financings
  • Represented TransForm Pharmaceuticals in multiple equity financings
  • Represented Hemera Biosciences in its Series A financing

Mergers & Acquisitions

  • Represented a public biotechnology company (Nasdaq) in its entering into a merger option to acquire a private biotechnology company
  • Represented Clarus Ventures in the reverse merger of VBI Vaccines (Nasdaq: VBIV) with Paulson Capital
  • Represented Orchid BioSciences (Nasdaq: ORCH) in its sale to Laboratory Corporation of America (NYSE: LH) 
  • Represented QIAGEN (Nasdaq: QGEN) in its purchase of SA Biosciences
  • Represented TransMolecular in its sale to Morphotek (a subsidiary of Eisai Co. (Tokyo Stock Exchange))
  • Represented Auspice in its sale to the ARRIS Group (Nasdaq: ARRS)
  • Represented EPIX Pharmaceuticals (Nasdaq: EPIX) in its merger with Predix Pharmaceuticals
  • Represented TransForm Pharmaceuticals in its sale to Johnson & Johnson (NYSE: JNJ)
  • Represented FastClick (Nasdaq: FSTC) in its sale to ValueClick (Nasdaq: VCLK)

Recognitions & Awards

  • Daniel J. Fern Award (Given annually to the graduate with the highest cumulative GPA)
  • Harry Kalus Award (Given annually to the graduate with the combination of the highest grade in the Massachusetts Practice course and the highest cumulative GPA)